COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

NAActive, not recruitingINTERVENTIONAL
Enrollment

1,222

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

March 16, 2026

Study Completion Date

December 31, 2026

Conditions
Multivessel Coronary Artery DiseaseIschemiaVulnerable PlaqueCoronary Artery Disease
Interventions
PROCEDURE

PCI revascularization strategy based on combined FFR and OCT assessment

PCI revascularization strategy based on combined FFR and OCT assessment All FFR ≤ 0.75 and Vulnerable plaque will be treated. VP defined as TCFA ( cap thickness ≤ 75 micron); Ruptured plaque; or Plaque erosion with \> 70 % AS or MLA \< 2.5 mm2.

PROCEDURE

PCI revascularization strategy based FFR assessment

PCI revascularization strategy based FFR assessment (all lesions with FFR≤0.80 will be treated)

Trial Locations (49)

Unknown

Monash Medical, Clayton

McGill University Health Centre, Montreal

Hamilton Health Sciences, Ontario

Niagara Health System - St. Catherines Site, Ontario

Aarhus University Hospital, Aarhus

North-Estonia Medical Centre, Tallinn

Centre Hospitalier Régional Universitaire de Lille, Lille

Clinique Louis Pasteur, Nancy

Charité - Universitätsmedizin Berlin, Berlin

Universitätsklinikum Frankfurt, Frankfurt

Apex Heart Institute, Ahmedabad

Apollo Hospitals, Bangalore

Post Graduate Institute of Medical education and Research, Chandigarh

Humanitas Research Hospital, Milan

Policlinico Universitario Fondazione Agostino Gemelli, Rome

National University Corporation Institute of Science Tokyo, Bunkyō City

Yokohama City University Medical Center, Yokohama

National Heart Institute, Kuala Lumpur

OLVG, Amsterdam

Albert Schweitzer Hospital, Dordrecht

Medisch Spectrum Twente, Enschede

Elisabeth-TweeSteden Hospital, Tilburg

Wellington Hospital, Wellington

Medical University of Silesia, Katowice

Jagiellonian University; John Paul II Hospital, Krakow

University Hospital Krakow, Krakow

Miedziowe Centrum Zdrowia, Lubin

Warsaw Medical University, Warsaw

Regional Specialist Hospital, Wroclaw

C.C. Iliescu Institute of Cardiology Bucharest, Bucharest

Nicolae Stăncioiu Heart Institute, Cluj-Napoca

Clinic Hospital Targu Mures & S.C. Cardio Med SRL, Târgu Mureş

Middle Slovak Institute of Cardiovascular Disease, Banská Bystrica

Hospital Bellvitge Barcelona, Barcelona

Hospital Clínic de Barcelona, Barcelona

Hospital Clinico San Carlos, Madrid

Hospital de La Princesa, Madrid

Hospital Gregorio Marañón Madrid, Madrid

Hospital Universitario Ramon y Cajal, Madrid

University Hospital La Paz, Madrid

Marqués de Valdecilla University Hospital, Santander

Hospital La Fe Valencia, Valencia

Linköping University, Linköping

Lund University, Lund

Universitetssjukhuset Örebro, Örebro

Danderyd Hospital, Stockholm

Far Eastern Memorial Hospital, New Taipei City

Cheng Hsin General Hospital, Taipei

National Taiwan University Hospital, Taipei

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Diagram B.V.

OTHER

NCT05333068 - COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events | Biotech Hunter | Biotech Hunter